Antibody Discovery Platform
Integrate advanced high-throughput screening platforms and leverage hybridoma, in vitro display, and single B cell screening techniques to rapidly discover therapeutic antibody candidates.
Scroll
Keymed Biosciences has established comprehensive R&D platforms in Chengdu and Shanghai, offering all key functions in biopharmaceutical discovery and development process. We have a macromolecular R&D center of 8,000 m2 and a cGMP–compliant pilot-scale workshop of antibody drugs in Chengdu Tianfu International Bio-town, equipped with cutting edge instruments.The cGMP compliant workshop can can support the manufacturing of clinical drugs which comply with the requirement of FDA,EMA and China NMPA.
Antibody Discovery Platform
Integrate advanced high-throughput screening platforms and leverage hybridoma, in vitro display, and single B cell screening techniques to rapidly discover therapeutic antibody candidates.
Proprietary nTCE Bispecific Antibody Platform
nTCE bispecific antibody platform specializes in the design and engineering of bispecific antibodies. This platform has generated three bispecific antibody candidates, including CM355（CD20xCD3), CM336（BCMAxCD3）and CM350（GPC3xCD3).
Process Development Platform
Construct and screen stable high-expressing cell strains, culture and purify cell, develop formulation of finish drug, and transfer from lab to production.
Quality Research Platform
Quality research and control platform features antibody drug characterization, purity and impurity analysis, and bioactivity analysis.
Commercial Manufacturing Platform
Commercial manufacturing park complies with GMP standards of NMPA, FDA and EMA is expected to operate in 2022, providing an additional capacity of 26,000 L. in first phase.
Autoimmunity
The causes of autoimmune diseases are complex. Stimulated by specific antigens, the immune system will be repeatedly or excessively activated, resulting in increased cytokine secretion, mediated immune response attacking normal tissues, or callus formation through compensatory pathways, thus impairing normal physiological functions.
Relying on our own antibody discovery and drug evaluation platform, we have developed highly-effective blocking antibodies for different types of autoimmune diseases to effectively reduce effector cell- and cytokine-mediated inflammatory responses, and then to influence the disease progress and to improve the quality of life in patients.
Oncology
The treatment of malignant tumors has significantly developed in recent years, especially the breakthrough of cancer immunotherapy. To further increase the clinical benefits to more patients and develop more effective treatment methods, we have cooperated with top domestic academic institutions and well-known companies in the industry to identify new targets, new mechanisms of action, and new combinations. At present, multiple molecules are in different stages of drug development.
| Research areas | Drug Candidate | Target(Modality) | Focused Indications | Lead Identification | Pre-Clinical | IND | Clinical Trials | Partner | Commercial Rights |
|---|---|---|---|---|---|---|---|---|---|
| Autoimmunity | CM310 | IL-4Rα(mAb) | Moderate-to-severe AD--Adults *BTD granted by CDE | Global | |||||
| Moderate-to-severe AD--Children & Adolescents | Global | ||||||||
| CRSwNP | Global | ||||||||
| Moderate-to-severe eosinophilic asthma |  | Global ex mainland China | |||||||
| SAR | Global | ||||||||
| CM326 | TSLP(mAb) | Moderate-to-severe AD | Global | ||||||
| CRSwNP | Global | ||||||||
| Moderate-to-severe asthma | | Global ex mainland China | |||||||
| COPD | Global ex mainland China | ||||||||
| CM338 | MASP-2(mAb) | IgA nephropathy | Global | ||||||
| Oncology | CMG901 *FTD & ODD granted by FDA | Claudin 18.2 (ADC) | Gastric and Other Solid tumors |
| Global | ||||
| CM313 | CD38(mAb) | RRMM, lymphoma and other hematological malignancies | Global | ||||||
| SLE | Global | ||||||||
| CM355 | CD20xCD3 (Bispecific) | Lymphoma |  | Global | |||||
| CM336 | BCMAxCD3 (Bispecific) | RRMM | Global | ||||||
| CM350 | GPC3xCD3 (Bispecific) | Solid tumors | Global | ||||||
| CM369 | CCR8 | Tumors | | Global | |||||
Swipe left and right to see more
In order to support the continuous improvement of R&D capabilities and the demand for large-scale commercial manufacture, Keymed's high-standard manufacturing park located in Tianfu International Bio-city, Chengdu, covering an area of 113 acres, is under construction. After completion, it can provide a fermentation capacity of 80,000 liters, which can meet the commercial production of 5-15 antibodies, becoming China's largest production base of antibody drugs in the central and western regions and the largest independent innovation antibody drug research and development center equipped with the capabilities of whole industry chain from drug discovery to commercialization. The first-stage construction has been completed which would provide an additional capacity of 16000L. The first production line has been started trial operation in October 2022.
Keymed has established strategic cooperation with leading pharmaceutical enterprises to accelerate the R&D progress and jointly explore more possibilities. Through mutual empowerment, we continue to promote the development of next-generation antibody therapies and bring more safe and effective treatments to patients. In the future, the Company will continue to actively seek more like-minded partners.
Tel：028-88610620
Email：pr@keymedbio.com
蜀ICP备2022006281号
